RxDoctor Payments Data

Jeremy Pollock, MD

Cardiovascular Disease · Towson, MDNPI 1124310289

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,880 of the $80,073 with a category attached, or 86.0%. 40 manufacturers reported payments, led by Boehringer Ingelheim at 53.6% of the total. Reporting peaked in 2019 at $22,233 and has fallen 93.7% since, to $1,398 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$80,073in general payments, 2019–2025

Across 558 payments — averaging $143.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$43K
  • Amarin Pharma, Inc.$21K
  • Scpharmaceuticals Inc.$4K
  • Lilly USA, LLC$3K
  • Medtronic$1K
  • Pfizer$1K
  • plus $7K from 34 others

What the payments were for

  • Speaking & faculty fees$68,88086%
  • Travel & lodging$1070%
  • Food & beverage$11,04914%
  • Education$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,073 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$506,993
Medicare patients
2,735
Services billed
8,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban583$681,107
EntrestoSacubitril/Valsartan183$236,174
JardianceEmpagliflozin154$200,214
XareltoRivaroxaban132$159,691
OzempicSemaglutide52$63,477
VascepaIcosapent Ethyl71$47,751
FarxigaDapagliflozin Propanediol29$39,607
Repatha SyringeEvolocumab53$36,601
Praluent PenAlirocumab64$34,399
WegovySemaglutide22$32,484
BrilintaTicagrelor40$29,315
Rosuvastatin Calcium1,115$20,899
Ezetimibe403$16,803
Icosapent Ethyl51$16,622
Repatha PushtronexEvolocumab19$14,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,084$681,107583 claims
NovartisEntresto$787$236,174183 claims
Boehringer IngelheimJardiance$42,898$200,214154 claims
Johnson & JohnsonXarelto$546$159,691132 claims
Novo NordiskOzempic, Wegovy$271$95,96274 claims
AstraZenecaFarxiga, Brilinta$500$68,92169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →